Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
C4 Therapeutics Inc is a biotechnology business based in the US. C4 Therapeutics shares (CCCC) are listed on the NASDAQ and all prices are listed in US Dollars. C4 Therapeutics employs 99 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Guided Investing
Our top pick for
Experienced Investors
| Latest market close | $43.89 |
|---|---|
| 52-week range | $23.63 - $51.21 |
| 50-day moving average | $46.07 |
| 200-day moving average | $39.62 |
| Wall St. target price | $60.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-2.54 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $43.89 from 2021-10-15
| 1 week (2021-10-11) | 4.97% |
|---|---|
| 1 month (2021-09-17) | -12.13% |
| 3 months (2021-07-19) | 11.14% |
| 6 months (2021-04-19) | 38.98% |
| 1 year (2020-10-16) | 74.58% |
|---|---|
| 2 years (2019-10-15) | N/A |
| 3 years (2018-10-15) | N/A |
| 5 years (2016-10-15) | N/A |
| Revenue TTM | $33.9 million |
|---|---|
| Gross profit TTM | $-44,273,000 |
| Return on assets TTM | -12.93% |
| Return on equity TTM | -32.69% |
| Profit margin | -257.05% |
| Book value | $8.61 |
| Market capitalisation | $2.1 billion |
TTM: trailing 12 months
There are currently 2.7 million C4 Therapeutics shares held short by investors – that's known as C4 Therapeutics's "short interest". This figure is 17.5% up from 2.3 million last month.
There are a few different ways that this level of interest in shorting C4 Therapeutics shares can be evaluated.
C4 Therapeutics's "short interest ratio" (SIR) is the quantity of C4 Therapeutics shares currently shorted divided by the average quantity of C4 Therapeutics shares traded daily (recently around 390990.01468429). C4 Therapeutics's SIR currently stands at 6.81. In other words for every 100,000 C4 Therapeutics shares traded daily on the market, roughly 6810 shares are currently held short.
To gain some more context, you can compare C4 Therapeutics's short interest ratio against those of similar companies.
However C4 Therapeutics's short interest can also be evaluated against the total number of C4 Therapeutics shares, or, against the total number of tradable C4 Therapeutics shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case C4 Therapeutics's short interest could be expressed as 0.06% of the outstanding shares (for every 100,000 C4 Therapeutics shares in existence, roughly 60 shares are currently held short) or 0.0626% of the tradable shares (for every 100,000 tradable C4 Therapeutics shares, roughly 63 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against C4 Therapeutics.
Find out more about how you can short C4 Therapeutics stock.
We're not expecting C4 Therapeutics to pay a dividend over the next 12 months.
C4 Therapeutics, Inc. , a biopharmaceutical company, develops novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable degrader that is in preclinical stage targeting IKZF1/3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma. The company is also developing CFT8634, an orally bioavailable degrader of BRD9, a protein target for synovial sarcoma and SMARCB1-deleted solid tumors; and BRAF V600E to treat melanoma, non-small cell lung cancer, colorectal cancer, and other solid malignancies, as well as RET to treat lung cancer, sporadic medullary thyroid cancers, and other solid malignancies. C4 Therapeutics, Inc. has strategic collaborations with F. Hoffman-La Roche Ltd.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
